Abstract: ＡＢＳＴＲＡＣＴＯｂｊｅｃｔｉｖｅ：To analyze the clinical features, treatment and prognosis of multiple myeloma patients associated with systemic light chain (AL) amyloidosis. 
Ｍｅｔｈｏｄｏｌｏｇｙ：Multiple myeloma patients associated with AL amyloidosis confirmed by biopsy at Jinling Hospital from July 2009 to December 2022 were studied. We retrospectively analyzed the clinical features, treatment and prognosis of the patients. 
Ｒｅｓｕｌｔｓ：Among the 71 patients, the primary presenting symptom was edema (84.5%), with IgG type M protein being the most common. The median plasma cell proportion was 15%. The majority of patients received treatment regimens containing bortezomib (32.4%) or thalidomide (25.4%). The overall hematologic response rate in the evaluated patients was 75.0%, including a complete response rate of 8.3%, a very good partial response rate of 389%, and a partial response rate of 27.8%. One (1/15, 6.7%) patient achieved cardiac response and 15 (15/36, 41.7%) patients achieved renal response. The median follow-up time was 16 (1.0～120.0) months, and the median survival time was 34 months. The survival rates at 6 months, 1 year, 2 years, and 4 years were 83.6%, 75.2%, 62.2%, and 43.0%, respectively. Age, plasma cell ratio, and N-terminal probrain natriuretic peptide levels were independently associated with patient prognosis.
Ｃｏｎｃｌｕｓｉｏｎ：Patients with multiple myeloma associated with AL amyloidosis have a dismal overall prognosis. Antiplasma cell therapy is effective but organ response rates are low. Age, severity of cardiac involvement, and tumor burden are independent risk factors for patient outcome.

Key words: multiple myeloma, light chain amyloidosis, clinical features, prognosis, risk factors